Claims
- 1. A chitin-binding, chitinase-inactive polypeptide comprising a chitin-binding fragment of the 54 C-terminal amino acids of human chitinase as set forth in SEQ ID NO: 2.
- 2. The polypeptide of claim 1 selected from the group consisting of a polypeptide having the sequence of amino acid residues 347 through 445 of SEQ ID NO: 2, polypeptide having the sequence of amino acid residues 374 through 445 of SEQ ID NO: 2, a polypeptide having the sequence of amino acid residues 392 through 445 of SEQ ID NO: 2, a polypeptide having the sequence of amino acid residues 395 through 445 of SEQ ID NO: 2, and a polypeptide having the sequence of amino acid residues 397 through 445 of SEQ ID NO: 2.
- 3. A polypeptide selected from the group consisting of polypeptides having the sequence of amino acid residues X through Y of SEQ ID NO: 2, wherein X is a consecutive integer from 347 through 397 and Y is 445.
- 4. A chitin-binding, chitinase-inactive polypeptide comprising a polypeptide of claim 3.
- 5. A fusion protein comprising the polypeptide of claim 1 fused to a heterologous polypeptide.
- 6. The fusion protein of claim 5 wherein the heterologous polypeptide is an enzyme.
- 7. A composition comprising the polypeptide of claim 1 and a physiologically acceptable diluent.
- 8. The composition of claim 7 further comprising a non-chitinase anti-fungal agent.
- 9. A composition comprising the polypeptide of claim 1 or 4 conjugated to an anti-fungal agent.
- 10. A method of treating fungal infection comprising the step of administering to a subject suffering from fungal infection a composition according to any one of claims 7 through 9.
- 11. The method of claim 10 further comprising the step of administering to said subject a non-chitinase anti-fungal agent.
- 12. A composition comprising the polypeptide of claim 1 or 4 conjugated to a detectable label.
- 13. The composition of claim 12 wherein the detectable label is selected from the group consisting of radioisotopes, fluorophores, dyes, electron-dense compounds and enzymes.
- 14. A method for determining the presence of chitin in a sample comprising the steps of:
(a) contacting the sample with the composition of claim 12 and (b) determining the amount of labelled polypeptide bound to chitin.
- 15. A kit for diagnosing the presence of chitin in a sample comprising the composition of claim 12.
- 16. A purified, isolated polynucleotide encoding the polypeptide of claim 1.
- 17. The polynucleotide of claim 16 that is DNA.
- 18. A vector comprising the DNA of claim 17.
- 19. A host cell stably transformed or transfected with the DNA of claim 17 in a manner allowing the expression in said host cell of a polypeptide encoded by said DNA.
- 20. A method for producing a polypeptide comprising a human chitinase fragment comprising culturing the host cell of claim 19 in a nutrient medium and isolating said polypeptide from said host cell or said nutrient medium.
- 21. A purified, isolated polypeptide produced by the method of claim 20.
- 22. A monoclonal antibody that specifically binds to an epitope within the 54 C-terminal amino acids of human chitinase as set forth in SEQ ID NO: 2.
- 23. The monoclonal antibody of claim 22 that competes with monoclonal antibody 243Q, produced by the hybridoma deposited under ATCC Accession No. ______, for binding to a chitin-binding, chitinase-inactive fragment of human chitinase.
- 24. The monoclonal antibody of claim 22 that competes with monoclonal antibody 243M, produced by the hybridoma deposited under ATCC Accession No. ______, for binding to a chitin-binding, chitinase-inactive fragment of human chitinase.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. Ser. No. 09/039,198 filed Mar. 12, 1998.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09267574 |
Mar 1999 |
US |
Child |
10161547 |
Jun 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09039198 |
Mar 1998 |
US |
Child |
09267574 |
Mar 1999 |
US |